Ibrexafungerp is efficacious in a neutropenic murine model of pulmonary mucormycosis as monotherapy and combined with liposomal amphotericin B

By sjmartinez • April 2, 2024

Gebremariam T, Alkhazraji S, Gu Y, Najvar LK, Borroto-Esoda K, Patterson TF, Filler SG, Wiederhold NP, Ibrahim AS. Ibrexafungerp is efficacious in a neutropenic murine model of pulmonary mucormycosis as monotherapy and combined with liposomal amphotericin B. Antimicrob Agents Chemother. 2024 Apr 1:e0154523. doi: 10.1128/aac.01545-23. Epub ahead of print. PMID: 38557112.

Tags: combination therapy, Harbor UCLA, Ibrexafungerp, infection model, Infectious Diseases, liposomal amphotericin B, mouse, mucor, mucormycosis, posaconazole, Publications, Rhizopus

Unusual painful pelvic masses: Extramedullary hematopoiesis with extramedullary multiple myeloma

Cai J, Varda M, Sin D, Overby H, Yeh JJ. Unusual painful pelvic masses: Extramedullary hematopoiesis with extramedullary multiple myeloma. Clin Case Rep. 2024 May[...]

Frailty in Patients on Dialysis

Chan GC, Kalantar-Zadeh K, Ng JK, Tian N, Burns A, Chow KM, Szeto CC, Li PK. Frailty in Patients on Dialysis. Kidney Int. 2024 May[...]

Efficacy of an oral lipid nanocrystal formulation of amphotericin B (MAT2203) in the neutropenic mouse model of pulmonary mucormycosis

Gu Y, Gebremariam T, Alkhazraji S, Youssef E, El-Gamal S, Matkovits T, Cobb J, Mannino R, Ibrahim AS. Efficacy of an oral lipid nanocrystal formulation[...]